Eleven weeks into the first Bundibugyo Ebola emergency, two long-absent tools arrived in 48 hours: the first patient dosed in a treatment trial and the first emergency-listed diagnostic. Confirmed cases still climbed to 1,481, and patient isolation, near 44 percent, sits below the level the CDC model says would break transmission. Governments meet in Geneva this week to try again on pandemic-era vaccine sharing.
New Ebola tools do not touch isolation or PABS, the two levers that actually decide the outbreak and its vaccines.
WHO's DON612 put the Bundibugyo outbreak at 1,481 confirmed cases and 454 deaths on 3 July, with patient isolation near 44 percent, still short of the level modelling says would break transmission.
SwitzerlandWHO's DON612, published 3 July 2026, put the Bundibugyo outbreak at 1,481 confirmed cases (1,460 DRC, 20 Uganda, 1 France), 454 deaths, a 30.9 percent case-fatality ratio and patient isolation near 44 percent, still short of the CDC model's 70 percent collapse threshold, while 102 healthcare workers had been infected and 25 had died.
At 44 percent isolation, DR Congo sits below the 70 percent the CDC model needs to force the outbreak's collapse.
The seventh Intergovernmental Working Group opened in Geneva on 6 July to break the deadlock over pandemic-era vaccine sharing, under a 17 July deadline Lula and Tedros called a deadline, not a milestone.
SwitzerlandThe seventh Intergovernmental Working Group session on the WHO Pandemic Agreement opened in Geneva on 6 July 2026, running to 17 July, to try again on the deadlocked PABS annex under a deadline that President Lula and Director-General Tedros named in a 15 June open letter to the G7, G20 and BRICS.
President Lula's signature marks the first time a head of state has pressed the PABS bargain, raising the political cost of a fourth deferral.
WHO dosed the first patient in a Bundibugyo Ebola treatment trial on 2 July, six weeks after naming the coalition behind it and after a regulatory hold that had stalled the drugs since late May.
SwitzerlandWHO enrolled the first patient in a randomised Bundibugyo Ebola treatment trial in Ituri Province on 2 July 2026, testing remdesivir, MBP134 and obeldesivir after DRC and Uganda regulators cleared the protocol that had stalled the drugs since late May.
Ituri's clinicians can now offer an investigational drug against a virus that had no licensed treatment through the outbreak's steepest weeks.
WHO added the first molecular test for Bundibugyo virus to its Emergency Use Listing on 2 July, as testing across the affected provinces climbed past 2,000 samples a day.
SwitzerlandWHO added the first molecular diagnostic for Bundibugyo virus to its Emergency Use Listing on 2 July 2026, as testing capacity in the affected DRC provinces rose from 200-400 to over 2,000 tests a day across ten laboratories.
Ten laboratories running over 2,000 tests a day shorten the lag between a suspected case and a confirmed one.
Gavi approved an extra $189 million for African vaccine manufacturing on 2 July, with $139 million to buy Africa-made vaccines and a first disbursement expected before year-end.
GAVI's board approved an extra $189 million for the African Vaccine Manufacturing Accelerator at a meeting that closed 2 July 2026, on top of the programme's existing $1 billion, with $139 million earmarked for Africa-made vaccines and first disbursements expected in the second half of 2026.
GAVI's money lets Africa finance vaccine plants, though the sample and technology access to fill them still hinges on the stalled PABS annex.
Two Chester County residents were confirmed with measles on 30 June, the first cases near Philadelphia since winter, as Pennsylvania's 2026 total reached a three-decade high.
Two Chester County, Pennsylvania residents were confirmed with measles on 30 June 2026, the first cases in the Philadelphia area since winter, as Pennsylvania's 2026 total reached 88 confirmed cases, its highest annual total in three decades, concentrated in Lancaster and Lebanon counties.
Philadelphia, a World Cup host city, sits about 30 miles from a measles chain, a proximity US surveillance was scaled up to watch.
Sideways to up. The outbreak's trajectory now hinges on whether Ituri and North Kivu isolation crosses 50 percent, the point where the CDC's R0=2.51 model's curve steepens toward the 70 percent that collapses the worst case. Two DONs running 24 June to 3 July show cases still climbing while isolation gains slow. Two external decision points could tip it further. IGWG7's 17 July deadline: a fourth PABS deferral would leave Gavi's $139 million in manufacturing money without the sample-access clause it needs. Washington's entry ban renewal, due around 21 July, has expanded scope on each of its three prior cycles without citing an epidemiological trigger; a fourth renewal would extend that pattern.
AI-assisted, human-edited under the editorial responsibility of Bannermedia Ltd. Reviewed by Ed Woodcock on 5 July 2026. Editorial standards.
